Avadel Pharmaceuticals plc
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$2.1B
-7558.2
-0.52
$169.12M
188
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
emptyResult
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Recently from Cashu
Avadel Pharmaceuticals Acquisition Under Investigation for Shareholder Rights Violations
Investigation into Avadel Pharmaceuticals Acquisition Raises Concerns Over Shareholder Rights Halper Sadeh LLC, a New York-based law firm specializing in investor rights, initiates an investigation in…
Alkermes Raises Acquisition Offer for Avadel Pharmaceuticals to $22.50 per Share
### Alkermes Enhances Acquisition Bid for Avadel Pharmaceuticals Alkermes plc has announced a significant increase in its bid to acquire Avadel Pharmaceuticals plc, offering a total transaction value…
Alkermes Bids $2.37 Billion for Avadel Pharmaceuticals to Enhance Portfolio
Alkermes Strengthens Pharmaceutical Portfolio with Avadel Acquisition Offer Alkermes plc has made a strategic move to enhance its position in the pharmaceutical industry by increasing its recommended…
Avadel Pharmaceuticals plc Evaluates Unsolicited Acquisition Offer from Lundbeck
Avadel Pharmaceuticals Faces Unsolicited Acquisition Proposal from Lundbeck Avadel Pharmaceuticals plc, a company recognized for its innovative pharmaceutical products, is currently navigating a pivot…